NCT01017926View on ClinicalTrials.gov

Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Healthy Volunteers
Interventions
DRUG

Triazolam

Tablets, 0.25 mg, single-dose, 1 period of 3 three days.

DRUG

Triazolam

Tablets, 0.25 mg, single-dose, 1 period of 3 three days.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Investigación Farmacológica y Biofarmacéutica

UNKNOWN

lead

Pfizer

INDUSTRY